



latest update 1/2016

RECOMMENDATION MANAGEMENT STAGE IV MELANOMA

These recommendations may serve as a guidance but need to be tuned according to the specific situation, among which the tumor kinetics, the type of clinical trial, ...

The most important options are in bold; the options are not necessarily in order of preference

	1° line	2° line	3° line
BRAF negative	<ul style="list-style-type: none"> > (anti-PD1)# > ipilimumab > (ipilimumab + anti-PD1)# > for solitary/few metastases: consider surgery* or gamma knife** > consider clinical trial 	<ul style="list-style-type: none"> > anti-PD1 > ipilimumab > (ipilimumab + anti-PD1)# > chemotherapy imatinib in case of c-kit mutation > consider clinical trial > consider best supportive care*** 	<ul style="list-style-type: none"> > chemotherapy > imatinib in case of c-kit mutation > consider clinical trial > consider best supportive care***
BRAF positive	<ul style="list-style-type: none"> > BRAF+MEKinhibitor > as in BRAF negative 	<ul style="list-style-type: none"> > as in BRAF negative > BRAF+MEKinhibitor in patients not responding to immunotherapy 	<ul style="list-style-type: none"> > as in BRAF negative

() # currently not yet available in Belgium

* mostly for one or few metastases of the brain, lung; for some metastases of GI tractus, skin/soft tissue, other

** mostly for one or few metastases of the brain

*** may also include surgery / radiotherapy